Influência da hormonioterapia na incidência de câncer em transexuais / Influence of hormone therapy on cancer incidence in transsexuals

Thamer Lucca Adorno Claudino da Costa, Fabrine dos Santos Silva Brandão, Wenya Vanessa Alves Figueiredo, Xisto Sena Passos, Fernanda Dorneles Morais

Abstract


Objetivo-. Este estudo teve como objetivo verificar a influência da hormonioterapia em transexuais com desenvolvimento de câncer. Métodos - Para esta revisão sistemática foi utilizado o método prisma. Pesquisamos na PubMed/Medline estudos publicados entre 2011 e 2020 que relataram a ocorrência de câncer em transexuais depois da hormonioterapia. Incluímos estudos de casos, série de casos, estudo de coorte, caso-controle e caso clínico, com inclusão de 36 artigos que apresentaram desenvolvimento alguma neoplasia após início da hormonioterapia. Resultados- Foram apresentados 55 casos, porém apenas 51 casos foram identificados com neoplasias após hormonioterapia, sendo 26 casos de FtM e 25 casos de MtF com seguintes cânceres: mama, cervical, fígado, próstata, testículo e neovaginal. Conclusão- A grande maioria dos casos que foram diagnosticados com câncer relataram o uso de hormônios exógenos antes do diagnóstico. Contudo, novos estudos para investigar e esclarecer o impacto da hormonioterapia no desenvolvimento de câncer em transexuais, para que novas medidas de tratamento e prevenção sejam fornecidas.


Keywords


Câncer em Transexuais, Câncer em Transgêneros, Câncer em Homens Transexuais, Câncer em Mulheres Transexuais, Efeitos Prolongados da Hormonioterapia em Transexuais.

References


Athayde AVL de. Transexualismo masculino. Arq. Bras. Endocrinol. Metabol. 2001;45(4):407–14.

American Psychological Association. Answers to your questions: For a better understanding of sexual orientation & homosexuality. Am. Psychol. Assoc. 2008;1–6.

SBPC, SBEM, CBR. Posicionamento Conjunto Transgênero. 2019;1–36.

Roselli CE. Neurobiology of gender identity and sexual orientation. J. Neuroendocrinol. 2018 Jul;30(7):e12562.

Grossman AH, Park JY, Russell ST. Transgender youth and suicidal behaviors: Applying the interpersonal psychological theory of suicide. J. Gay Lesbian Ment. Health. 2016 Oct 30;20(4):329–49.

Nguyen HB, Loughead J, Lipner E, Hantsoo L, Kornfield SL, Epperson CN. What has sex got to do with it? The role of hormones in the transgender brain. Neuropsychopharmacology. 2019 Jan 5;44(1):22–37.

Ardebili ME, Janani L, Khazaei Z, Moradi Y, Baradaran HR. Quality of life in people with transsexuality after surgery: a systematic review and meta-analysis. Health Qual. Life Outcomes. 2020 Dec 3;18(1):1–11.

Fernandez J, Tannock L. Metabolic Effects Of Hormone Therapy In Transgender Patients. Endocr. Pract. 2016 Apr;22(4):383–8.

Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2009 Sep 1;94(9):3132–54.

Wierckx K, Elaut E, Declercq E, Heylens G, Cuypere G De, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: A case-control study. Eur. J. Endocrinol. 2013;169(4):471–8.

Joint R, Chen Z, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG An Int. J. Obstet. Gynaecol. 2018 Nov;125(12):1505–12.

Gooren L, Bowers M, Lips P, Konings IR. Five new cases of breast cancer in transsexual persons. Andrologia. 2015 Dec;47(10):1202–5.

Mancini I, Rotilio A, Coati I, Seracchioli R, Martelli V, Meriggiola MC. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review. Gynecol. Endocrinol. 2018 Jun;34(6):456–9.

Eismann J, Heng YJ, Fleischmann-Rose K, Tobias AM, Phillips J, Wulf GM, et al. Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. Clin. Breast Cancer. 2019 Feb;19(1):e12–e19.

Shao T, Grossbard ML, Klein P. Breast Cancer in Female-to-Male Transsexuals: Two Cases With a Review of Physiology and Management. Clin. Breast Cancer. 2011 Dec;11(6):417–9.

Nikolic D V, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic V V., Zdravkovic D, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. World J. Surg. Oncol. 2012 Dec 28;10(1):1–4.

Gooren LJ, Trotsenburg MAA van, Giltay EJ, Diest PJ van. Breast Cancer Development in Transsexual Subjects Receiving Cross-Sex Hormone Treatment. J. Sex. Med. 2013 Dec;10(12):3129–34.

Brown GR. Breast Cancer in Transgender Veterans: A Ten-Case Series. LGBT Heal. 2015 Mar;2(1):77–80.

Katayama Y, Motoki T, Watanabe S, Miho S, Kimata Y, Matsuoka J, et al. A very rare case of breast cancer in a female-to-male transsexual. Breast Cancer. 2016;23(6):939–44.

Barghouthi N, Turner J, Perini J. Breast Cancer Development in a Transgender Male Receiving Testosterone Therapy. Case Rep. Endocrinol. 2018 Dec 31;2018:1–3.

Renterghem SMJ Van, Dorpe J Van, Monstrey SJ, Defreyne J, Claes KEY, Praet M, et al. Routine histopathological examination after female-to-male gender-confirming mastectomy. Br. J. Surg. 2018;105(7):885–92.

Treskova I, Hes O, Bursa V. Long-term hormonal therapy resulting in breast cancer in female-to-male transsexual: Case report. Med. (United States). 2018;97(52):1–2.

Tanini S, Fisher AD, Meattini I, Bianchi S, Ristori J, Maggi M, et al. Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation. Clin. Breast Cancer. 2018;19(2):e271–e275.

Fundytus A, Saad N, Logie N, Roldan Urgoiti G. Breast cancer in transgender female‐to‐male individuals: A case report of androgen receptor‐positive breast cancer. Breast J. 2020 May 20;26(5):1007–12.

Chotai N, Tang S, Lim H, Lu S. Breast cancer in a female to male transgender patient 20 years post‐mastectomy: Issues to consider. Breast J. 2019 Nov 4;25(6):1066–70.

Beswick A, Corkum M, D’Souza D. Locally advanced cervical cancer in a transgender man. Can. Med. Assoc. J. 2019 Jan 21;191(3):E76–E78.

Light M, McFarlane T, Ives A, Shah B, Lim E, Grossmann M, et al. Testosterone therapy considerations in oestrogen, progesterone and androgen receptor positive breast cancer in a transgender man. Clin. Endocrinol. (Oxf). 2020 Sep 26;93(3):355–7.

Lin AJ, Baranski T, Chaterjee D, Chapman W, Foltz G, Kim H. Androgen-receptor-positive hepatocellular carcinoma in a transgender teenager taking exogenous testosterone. Lancet. 2020;396(10245):198.

Fledderus AC, Gout HA, Ogilvie AC, Loenen DKG van. Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. The Breast. 2020 Oct;53:92–100.

Kopetti C, Schaffer C, Zaman K, Liapi A, Summa PG di, Bauquis O. Invasive Breast Cancer in a Trans Man After Bilateral Mastectomy: Case Report and Literature Review. Clin. Breast Cancer. 2020 Nov;1–4.

Pattison ST, Mclaren BR. Triple negative breast cancer in a male-to-female transsexual. Intern. Med. J. 2013;43(2):203–05.

Turo R, Jallad S, Cross WR, Prescott S. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can. Urol. Assoc. J. 2013 Aug 19;7(7–8):E544–E546.

Fernandes HM, Manolitsas TP, Jobling TW. Carcinoma of the Neovagina After Male-to-Female Reassignment. J. Low. Genit. Tract Dis. 2014 Apr;18(2):E43–E45.

Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, et al. Breast Cancer in Male-to-Female Transsexuals: Use of Breast Imaging for Detection. Am. J. Roentgenol. 2014 Dec;203(6):W735–W740.

Sattari M. Breast cancer in male-to-female transgender patients: A case for caution. Clin. Breast Cancer. 2015;15(1):e67–e69.

Teoh ZH, Archampong D, Gate T. Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature? Case Reports. 2015 May 20;2015:1–3.

Gondusky CJ, Kim MJ, Kalantari BN, Khalkhali I, Dauphine CE. Examining the Role of Screening Mammography in Men at Moderate Risk for Breast Cancer: Two Illustrative Cases. Breast J. 2015 May;21(3):316–7.

Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, et al. Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization. JAMA. 2006 Nov 15;296(19):2316–17.

Corman V, Potorac I, Manto F, Dassy S, Segers K, Thiry A, et al. Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation. Endocr. Relat. Cancer. 2016 May;23(5):391–7.

Ellent E, Matrana MR. Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery. Clin. Genitourin. Cancer. 2016 Apr;14(2):e207–e209.

Sharif A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, Bosland M, Guzman G, et al. The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? Prostate. 2017;77(8):824–28.

Chandhoke G, Shayegan B, Hotte SJ. Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report. J. Med. Case Rep. 2018;12(1):1–5.

Kvach EJ, Hyer JS, Carey JC, Bowers M. Testicular Seminoma in a Transgender Woman: A Case Report. LGBT Heal. 2019;6(1):40–2.

Fierz R, Ghisu G-P, Fink D. Squamous Carcinoma of the Neovagina after Male-to-Female Reconstruction Surgery: A Case Report and Review of the Literature. Case Rep. Obstet. Gynecol. 2019 Jan 16;2019(4820396):1–7.

Wang G, Ferguson D, Ionescu DN, Hoang L, Barrett S, Niekerk D Van, et al. HPV-Related Neovaginal Squamous Cell Carcinoma Presenting as Lung Metastasis after Male-to-Female Gender Confirmation Surgery. Case Rep. Oncol. 2020;13(1):17–22.

Lienhoop T, Smetko M, Green L. Breast cancer in transgender women: A case report. Clin. Imaging. 2020 Dec;68:20–23.

Elshimy G, Tran K, Harman SM, Correa R. Unmasked Testicular Seminoma During Use of Hormonal Transgender Woman Therapy: A Hidden hCG-Secreting Tumor. J. Endocr. Soc. 2020 Jul 1;4(7):1–8.

Nehlsen AD, Bhardwaj A, Weltz C, Green S. Triple Negative Breast Cancer in a Male to Female Transgender Patient: A Case Report and Literature Review. Adv. Radiat. Oncol. 2020;5(5):1083–9.

Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men. Cancer. 2004 Jul 1;101(1):51–7.

Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, et al. Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women. Cancer Epidemiol. Biomarkers Prev. 2010 Feb;19(2):492–502.

Yager JD, Davidson NE. Estrogen Carcinogenesis in Breast Cancer. N. Engl. J. Med. 2006 Jan 19;354(3):270–282.

Clemons M, Goss P. Estrogen and the Risk of Breast Cancer. N. Engl. J. Med. 2001 Jan 25;344(4):276–85.

Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003 Oct 1;5(5):239–47.

Kotsopoulos J, Narod SA. Androgens and breast cancer. Steroids. 2012;77(1–2):1–9.

Key TJA, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol. 1988 Jan;24(1):29–43.

Bernstein L, Ross RK. Endogenous Hormones and Breast Cancer Risk. Epidemiol. Rev. 1993;15(1):48–65.

Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A Prospective Study of Endogenous Estrogens and Breast Cancer in Postmenopausal Women. JNCI J. Natl. Cancer Inst. 1995 Feb 1;87(3):190–7.

Key T, Appleby P, Barnes I, Reeves G. Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies. CancerSpectrum Knowl. Environ. 2002 Apr 17;94(8):606–16.

MUTI P. The Role of Endogenous Hormones in the Etiology and Prevention of Breast Cancer: The Epidemiological Evidence. Ann. N. Y. Acad. Sci. 2004 Dec 1;1028(1):273–82.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997 Oct;350(9084):1047–59.

Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, Ghissassi F El. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005 Aug;6(8):552–3.

Gompel A. Hormones et cancers du sein. Presse Med. 2019 Oct;48(10):1085–91.

Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: Role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol. Biomarkers Prev. 2012;21(7):1038–48.

Liede A, Karlan BY, Narod SA. Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2 : A Review of the Literature. J. Clin. Oncol. 2004 Feb 15;22(4):735–42.

Kornegoor R, Verschuur-Maes AHJ, Buerger H, Hogenes MCH, Bruin PC De, Oudejans JJ, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod. Pathol. 2012;25(3):398–404.

Burcombe R., Makris A, Pittam M, Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. The Breast. 2003 Aug;12(4):290–3.

Hage JJ, Dekker JJML, Karim RB, Verheijen RHM, Bloemena E. Ovarian Cancer in Female-to-Male Transsexuals: Report of Two Cases. Gynecol. Oncol. 2000 Mar;76(3):413–5.

Anderson GL, Limacher M. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004 Apr 14;291(14):1701–12.

Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, et al. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women’s contraceptive and reproductive experiences study. Am. J. Epidemiol. 2011;173(1):38–47.

Woolcott CG, Maskarinec G, Pike MC, Henderson BE, Wilkens LR, Kolonel LN. Breast cancer risk and hysterectomy status: The Multiethnic Cohort study. Cancer Causes Control. 2009;20(5):539–47.

Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000 Mar;21(3):427–33.

Carmo GM do, Ortegal GHP de C, Santana IF, Xavier IR, Silva NCD, Pereira YA, et al. Análise do risco de trombose em transexuais devido a terapia hormonal/Thrombosis risk analysis in transsexuals due to hormonal therapy. Brazilian J. Dev. 2020;6(9):71580–71592.

Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur. J. Endocrinol. 2008 Sep;159(3):197–202.

Simard J, Dumont M, Soucy P, Labrie F. Perspective: Prostate cancer susceptibility genes. Endocrinology. 2002;143(6):2029–40.




DOI: https://doi.org/10.34117/bjdv7n6-150

Refbacks

  • There are currently no refbacks.